肝细胞癌是当前全球癌症相关死亡的第六大原因，尽管慢性乙型肝炎感染的发病率已有所下降。这是由于代谢疾病如代谢综合征、糖尿病、肥胖症和非酒精性脂肪性肝炎（NASH）的普及。目前在HCC中蛋白激酶抑制剂治疗是非常激进而不具有治愈性的。从这个角度出发，转向代谢治疗可能是一种有前途的选择。在这里，我们回顾了HCC中代谢紊乱和治疗方法针对代谢通路的当前知识。我们还提出了多靶点代谢方法作为HCC药理学的可能新选择。

Hepatocellular carcinoma is today the sixth leading cause of cancer-related death worldwide, despite the decreased incidence of chronic hepatitis infections. This is due to the increased diffusion of metabolic diseases such as the metabolic syndrome, diabetes, obesity, and nonalcoholic steatohepatitis (NASH). The current protein kinase inhibitor therapies in HCC are very aggressive and not curative. From this perspective, a shift in strategy toward metabolic therapies may represent a promising option. Here, we review current knowledge on metabolic dysregulation in HCC and therapeutic approaches targeting metabolic pathways. We also propose a multi-target metabolic approach as a possible new option in HCC pharmacology.